Antifungal Treatment Guidelines for Adolescents

Introduction to Antifungal Agents

The American Academy of Pediatrics and the Infectious Diseases Society of America recommend fluconazole as the first-line agent for invasive candidiasis in adolescents, with a dosing regimen of 8-12 mg/kg once daily, due to its excellent efficacy and tolerability 1, 2

For adolescents with invasive fungal infections or who are immunocompromised, fluconazole remains the first-line treatment at 8-12 mg/kg once daily, but alternative agents like voriconazole, posaconazole, and itraconazole may be considered for broader coverage, with voriconazole dosed at 9 mg/kg twice daily orally and posaconazole at 200 mg three times daily, due to their ability to cover Aspergillus and other opportunistic molds 1, 2, 3, 4, 5
The use of voriconazole, posaconazole, and itraconazole requires therapeutic drug monitoring to ensure therapeutic levels and avoid toxicity, with target trough levels of ≥1 mg/L for voriconazole, ≥0.7 mg/L for posaconazole, and ≥0.5 mg/L for itraconazole 1, 2, 3, 4, 5

All azole antifungals have significant interactions with immunosuppressants, including cyclosporine, tacrolimus, and sirolimus, necessitating careful medication reconciliation and potential dose adjustments, as recommended by the Clinical Microbiology and Infection society 4, 5, 6
Therapeutic drug monitoring is strongly recommended for voriconazole, posaconazole, and itraconazole to ensure therapeutic levels and avoid toxicity, due to the high risk of treatment failure with subtherapeutic levels 1, 2, 3, 4, 5

The Infectious Diseases Society of America recommends an algorithmic approach to antifungal treatment, starting with identification of infection type and severity, followed by selection of the appropriate antifungal agent, checking for drug interactions, implementing monitoring, and ensuring adequate treatment duration, to minimize the risk of treatment failure and improve patient outcomes 1, 2, 4, 5, 6, 7, 8